AKF launches campaign to involve underrepresented groups in kidney disease clinical trials
[ad_1]
February 24, 2022
1 min read
The American Kidney Fund announced a new campaign focused on encouraging “communities of color” to participate in kidney disease clinical trials.
According to the press release, Black, Hispanic, Native American and Asian American individuals make up less than 16% of clinical trial participants. The new campaign is designed to provide underrepresented groups with information and practical tools that explain the clinical trial process and how it can benefit participants.
LaVarne A. Burton
“Racial bias among health care practitioners also unfortunately plays a role in the lack of diversity in clinical trials. In many cases, people of color would be willing to participate in a clinical trial if only it were recommended to them by their provider,” LaVarne A. Burton, president and CEO of AKF, said in the release. “We hope that by shining a light on these systemic issues, and equipping communities of color with information about clinical trials and how to engage with their care team, we can improve representation and ensure new therapies work for the people who need them the most.”
This campaign has been launched shortly after AKF’s Looped in on Lupus Nephritis campaign, a program intended to improve care among women with lupus in underrepresented groups. Both campaigns are supported financially by GlaxoSmithKline.
Race and Medicine
[ad_2]
Source link
